Skip to main content
SpringerLink
Log in

Prostate Cancer Vaccine — Northwest Biotherapeutics

CaPVax, DC1/HRPC, DCVax — Prostate

  • Adis R&d Profile
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Wang L, Elgamal A, Shankar G, et al. rPSMA-Loaded autologous dendritic cell vaccine (CaPVax) safely activates cellular and humoral immune responses against androgen-independent prostate cancer. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12; San Francisco, 20(2): 222

    Google Scholar 

  2. Shankar G, Kelley H, Lodge A, et al. Monitoring immune responses of prostate cancer patients vaccinated with prostate-specific membrane antigen (PSMA) protein-loaded dendritic cells in a phase I/II clinical trial. 92nd Annual Meeting of the American Association for Cancer Research; 2001 Mar 24–28; New Orleans, 42: 26–7

    Google Scholar 

  3. Salgaller ML, Lodge PA, Bader RR, et al. Monitoring the immune reactivity of prostate cancer patients vaccinated with dendritic cells expressing prostate-specific membrane antigen peptides during a phase II clinical trial. 90th Annual Meeting of the American Association for Cancer Research; 1999 Apr 10; Philadelphia, 576

  4. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999 Jul 1; 40: 125–9

    Article  PubMed  CAS  Google Scholar 

  5. Simmons SJ, Tjoa BA, Rogers M, et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999 Jun 1; 39: 291–7

    Article  PubMed  CAS  Google Scholar 

  6. Lodge PA, Jones LA, Bader RA, et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000 Feb 15; 60: 829–33

    PubMed  CAS  Google Scholar 

  7. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996 Jun; 29: 371–80

    Article  PubMed  CAS  Google Scholar 

  8. Northwest Biotherapeutics Inc. Northwest Biotherapeutics, Inc. to present new phase I/II clinical data on promising prostate cancer treatment [media release 2002 Mar 5]. Available from URL: http://www.nwbio.com [Accessed 2002 July 2]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prostate Cancer Vaccine — Northwest Biotherapeutics. BioDrugs 16, 226–227 (2002). https://doi.org/10.2165/00063030-200216030-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200216030-00010

Search

Navigation